Recombinant Human Interleukin-17 receptor (IL-17 R)

Recombinant Human Interleukin17 receptor (IL17 R) is a valuable tool in research applications focused on immunology, inflammation, autoimmunity, and hostpathogen interactions because it enables precise modulation and interrogation of the IL17 signaling pathway.

Key reasons to use recombinant IL17 R in research:

• Blocking IL17 Signaling: Recombinant IL17 R, especially in the form of soluble receptor or Fc fusion proteins, acts as a decoy receptor that binds IL17A and related cytokines, preventing them from interacting with cellsurface IL17 receptors and thus inhibiting downstream proinflammatory signaling. This is critical for dissecting the role of IL17 in disease models and for validating therapeutic strategies targeting this pathway.

• Studying Inflammatory Mechanisms: IL17 and its receptor are central to the recruitment of neutrophils and the amplification of inflammatory responses. Using recombinant IL17 R allows researchers to modulate these processes in vitro and in vivo, helping to clarify the contribution of IL17 signaling to diseases such as rheumatoid arthritis, psoriasis, and chronic pain.

• Host Defense and Autoimmunity: IL17 R is required for effective host defense against microbial infections and is implicated in the progression of autoimmune diseases from inflammation to tissue destruction. Recombinant IL17 R can be used to model or block these processes, providing insights into both protective and pathological roles of IL17 signaling.

• Therapeutic Target Validation: In preclinical models, administration of recombinant IL17 R or its fusion proteins has been shown to reduce disease severity in models of arthritis and other inflammatory conditions, supporting its use in drug development and mechanistic studies.

• Biochemical and Cellbased Assays: Recombinant IL17 R is used in binding assays, neutralization studies, and as a standard or competitor in ELISA and other immunoassays to quantify IL17 or to screen for inhibitors of the IL17/IL17R interaction.

Additional context:

• IL17 R is broadly expressed on various cell types, including immune and nonimmune cells, and mediates the effects of several IL17 family cytokines.
• The receptor is essential for the activation of downstream signaling pathways such as NFκB and MAPKs, which regulate the expression of cytokines, chemokines, and other inflammatory mediators.
• Recombinant forms are typically engineered for high purity, low endotoxin, and functional activity, making them suitable for sensitive in vitro and in vivo applications.

In summary, recombinant human IL17 R is a critical reagent for dissecting IL17 biology, validating therapeutic targets, and developing new interventions for inflammatory and autoimmune diseases.

Recombinant Human Interleukin17 receptor (IL17 R) can be used as a standard for quantification or calibration in ELISA assays specifically designed to measure IL17 R, provided the assay protocol supports recombinant protein standards.

For ELISA assays targeting IL17 R (the receptor), recombinant human IL17 R is commonly supplied as a standard in commercial ELISA development kits. These kits include protocols and reagents optimized for quantifying both natural and recombinant IL17 R in biological samples. The standard curve generated from serial dilutions of recombinant IL17 R allows for accurate quantification of IL17 R concentrations in unknown samples, as long as the assay is validated for this purpose and the recombinant protein is of high purity and properly characterized.

Key considerations:

• Assay specificity: Ensure your ELISA is designed to detect IL17 R, not IL17A or other IL17 family cytokines. Using IL17 R as a standard in an IL17A assay would be inappropriate, as the antibodies are specific to the ligand, not the receptor.
• Standard preparation: Follow the recommended protocol for preparing and diluting the recombinant IL17 R standard. The standard curve should cover the expected concentration range of your samples.
• Matrix effects: If quantifying IL17 R in complex matrices (e.g., serum, plasma), validate recovery and linearity using the recombinant standard in those matrices, as matrix components can affect assay performance.
• Documentation: Use the provided datasheet or protocol for your specific ELISA kit to ensure compatibility and optimal results.

Summary Table: Use of Recombinant IL17 R as ELISA Standard

In conclusion: If your ELISA is designed to measure IL17 R, recombinant human IL17 R is suitable as a standard for quantification and calibration. Always confirm compatibility with your assay protocol and validate performance in your sample matrix.

Recombinant Human Interleukin17 receptor (IL17 R) has been validated in published research for several key applications, primarily in the context of immunology, inflammation, and autoimmune disease models.

Validated Applications in Published Research:

• Bioassays: Recombinant IL17 R is widely used in cellbased bioassays to study IL17 signaling, receptorligand interactions, and downstream effects such as cytokine and chemokine production, neutrophil recruitment, and inflammatory responses in various human cell types.
• Neutralization/Blocking Studies: It is used to assess the ability of antibodies or small molecules to block IL17/IL17R interactions, which is critical for evaluating potential therapeutics targeting the IL17 pathway in autoimmune and inflammatory diseases.
• ELISA Development: Recombinant IL17 R has been used as a standard or capture reagent in ELISA assays for the detection and quantification of IL17 or its receptor in biological samples.
• Mechanistic Studies: Research has employed recombinant IL17 R to dissect the signaling pathways activated by IL17, including activation of fibroblasts, endothelial cells, and immune cells, and to study the expression of adhesion molecules and chemokines.
• Disease Modeling: Recombinant IL17 R is used in preclinical models of diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and chronic pain to investigate the role of IL17 signaling and to test the efficacy of IL17/IL17Rtargeted therapies.

Key Research Contexts:

• Autoimmune and Inflammatory Diseases: Studies have validated its use in models of rheumatoid arthritis, psoriasis, and inflammatory bowel disease, both in vitro (human cells) and in vivo (animal models), to understand disease mechanisms and evaluate therapeutic interventions.
• Neuroinflammation and Pain: IL17/IL17R signaling has been studied in the context of chronic pain and neuroinflammation, with recombinant IL17 R used to demonstrate the pathway’s contribution to pain sensitization and neuroimmune interactions.
• Cancer and Tumor Immunology: Some studies have used recombinant IL17 R to explore its role in tumorassociated inflammation and immune cell recruitment.

Summary Table:

References to Specific Research:

• Studies have shown IL17/IL17R upregulation in rodent models and human samples of chronic pain, and that IL17R antibodies can attenuate pain and autoimmune disease symptoms.
• Recombinant IL17 R has been used to demonstrate the efficacy of novel biologics in neutralizing IL17driven inflammation in preclinical models of rheumatoid arthritis and IBD.
• It is also used in mechanistic studies to show IL17RA/Cdependent activation of fibroblasts and endothelial cells, leading to increased cytokine and chemokine expression.

Conclusion:
Recombinant Human IL17 receptor (IL17 R) is validated for use in bioassays, neutralization/blocking studies, ELISA development, mechanistic signaling studies, and disease modeling, particularly in the fields of immunology, inflammation, autoimmune disease, and neuroinflammation.

To reconstitute and prepare Recombinant Human Interleukin17 receptor (IL17 R, also known as IL17RA) protein for cell culture experiments, follow these bestpractice steps:

1. Reconstitution

   • Briefly centrifuge the vial before opening to ensure all lyophilized protein is at the bottom.
   • Add sterile distilled water or buffer (such as PBS, pH 7.2–7.4) to achieve a final concentration of 0.1–1.0 mg/mL.
   • Gently mix by pipetting up and down or swirling. Do not vortex, as this can denature the protein.
   • Allow the protein to fully dissolve at room temperature for 10–15 minutes.

2. Carrier Protein (Optional but Recommended)

   • For enhanced stability, especially at low concentrations or for longterm storage, add a carrier protein such as 0.1–1% BSA or HSA to the buffer.
   • This is particularly important if you plan to store aliquots or use the protein at concentrations below 0.1 mg/mL.

3. Aliquoting and Storage

   • Aliquot the reconstituted protein into small volumes to avoid repeated freezethaw cycles, which can degrade the protein.
   • Store aliquots at 2–8°C for up to one week, or at –20°C to –80°C for longterm storage.
   • Avoid multiple freezethaw cycles.

4. Preparation for Cell Culture

   • Before adding to cell culture, dilute the protein to the desired working concentration using cell culture medium or sterile PBS with carrier protein if needed.
   • Filtersterilize the final solution if sterility is required and the buffer composition allows.

Summary Table: IL17R Protein Reconstitution and Handling

Additional Notes:

• Always consult the specific product datasheet for any manufacturerspecific recommendations, as buffer composition and protein stability may vary.
• If using for functional assays, confirm activity postreconstitution using a relevant bioassay.

These guidelines are based on standard protocols for recombinant cytokine receptor proteins and are consistent with published datasheets and technical manuals for IL17RA/IL17R.